The benefit-risk profile for Secura Bio, Inc.’s Copiktra (duvelisib) is not favorable in its current indication for third-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), a US Food and Drug Administration advisory committee said on 23 September.
In voting 8-4 that the drug’s benefits do not outweigh its risks, Oncologic Drugs Advisory Committee members in the majority...





